Evaluating oral selexipag in PAH: Insights on survival, safety and dosing patterns from the complete observation period of GRIPHON and its open-label extension

By afschroeder • November 17, 2025

McLaughlin VV, Howard L, Elwing J, Fernandes CC, Gaine S, Galiè N, Oudiz RJ, Stefani M, Stickel S, Strachan P, Tamura Y, Kim NH. Evaluating oral selexipag in PAH: Insights on survival, safety and dosing patterns from the complete observation period of GRIPHON and its open-label extension. J Heart Lung Transplant. 2025 Nov 14:S1053-2498(25)02393-9. doi: 10.1016/j.healun.2025.11.007. Epub ahead of print. PMID: 41242357.

Tags: Cardiology/Epi, Harbor UCLA, Long-term safety, long-term survival, open-label extension, Publications, pulmonary arterial hypertension, Selexipag

Decontrasted Image Registration Improves Quantification of Extracellular Volume and Fractional Myocardial Blood Volume

Lu M, Mahmoudi M, Nguyen KL, Xie Y. Decontrasted Image Registration Improves Quantification of Extracellular Volume and Fractional Myocardial Blood Volume. NMR Biomed. 2025 Dec;38(12):e70179.[...]

Author Correction: Kilohertz volumetric imaging of in vivo dynamics using squeezed light field microscopy

Wang Z, Zhao R, Wagenaar DA, Espino D, Sheintuch L, Benshlomo O, Kang W, Zhu E, Lee CK, Schmidt WC, Pammar A, Wang J, Wong[...]

Immune Checkpoint Inhibitor-Associated Uveitis: Predictors and Survival Impact

Chew L, Feng J, Hutchins E, Stein-Merlob AF, Yang EH, Lechner MG, Tsui E. Immune Checkpoint Inhibitor-Associated Uveitis: Predictors and Survival Impact. Ophthalmol Retina. 2025[...]